

Completed Acquisition by Rentokil Initial plc of Cannon Hygiene Limited

Consent to certain actions for the purposes of the Final Undertakings made by the Competition and Markets Authority on 16 April 2019

We refer to your email of the 17 May 2019 and associated attachment requesting that the Competition and Markets Authority (**CMA**) consents to a derogation to the Final Undertakings of 16 April 2019.

Under the Final Undertakings, save for written consent by the CMA, Rentokil and Cannon are required to take specified actions to ensure that the Rentokil business and the Cannon business are carried on separately and refrain from taking any action which might prejudice a reference under section 22 of the Enterprise Act or impede the taking of any remedial action by the CMA.

The terms defined in the Final Undertakings have the same meaning in this letter.

After due consideration of your request for derogations from the Final Undertakings, based on the information received from you and in the particular circumstances of this case, Rentokil and Cannon may carry out the following actions, in respect of the specific paragraphs:

1. Paragraph 5.2(a) and 5.2(m) of the Final Undertakings

In order to enable Rentokil to explore its options in relation to the sale of the Divestiture Package (as defined in the final undertakings accepted by the CMA on 16 April 2019), Rentokil has requested that [%] be given permission to discuss the Divestiture Package with potential suitable purchasers and assist with negotiations on behalf of Rentokil. Neither of these individuals have an operational or customerfacing role in relation to washroom services in the UK.

To assist Rentokil in securing the divestment of the Divestiture Package, the CMA consents to [🎉] being provided with high-level information concerning the Cannon business and for these individuals to discuss that information with third parties, provided that:

- (a) these actions are restricted to the named individuals;
- (b) the named individuals adhere to signed NDAs as agreed with the CMA;

- (c) the named individuals keep the Monitoring Trustee informed; and
- (d) potentially interested buyers also sign an NDA.

Susan Hankey Remedy Group Chair

20 May 2019